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Through collaboration and innovation, UNLV researchers are changing the way we think about the brain.

PORTRAITS BY JOSH HAWKINS
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Jeff Kinney chose to join the UNLV psychology faculty in 2007 for many reasons, but the
one that clinched the deal was the opportunity to build out the neuroscience area.
“The prospect of building a program from the ground up was far more appealing to me

than joining an already established group,” says Kinney. “For me, carving out something
new had great appeal.”
Today, Kinney’s hopes—and his efforts in his first several years here—are coming to

fruition. In the last year, he led a UNLV research team that joined with the Cleveland Clinic
Lou Ruvo Center for Brain Health to obtain an $11.1 million grant from the National Institutes
of Health for advanced study of both Parkinson’s and Alzheimer’s diseases. Additionally,
the department now offers a Ph.D. area of emphasis in neuroscience, with plans to offer a
stand-alone neuroscience doctorate soon. The department also recently launched a
neuroscience minor, in which more than 100 undergraduates are currently enrolled.
“And now the department is approaching a critical mass of faculty in neuroscience, and
faculty from other departments are collaborating with us as well,” he says. “This will enable
us to begin building a center of excellence in neuroscience that will dramatically help with
securing research funding in the form of collaborative and individual grants.”
One of the keys to the successful acquisition of research dollars, he notes, is the inclusion
of collaborators, both on and off campus. Kinney and his team are working with several
UNLV faculty members studying myriad topics. The following profiles offer a glimpse into
the growing neuroscience research being conducted on the UNLV campus.

Patterns of Activity

A

s a 19-year-old education major, Rochelle
Hines’ career ambition was to work with
schoolchildren who have special needs.
Then she enrolled in an elective course called
“Brain and Behavior.”
“I was captivated,” Hines says. “By the second week of this class, I had changed my major
and started working in the lab of my professor.”
The undergraduate research experience that
followed enabled Hines to use various advanced
technologies—electron microscopy among
them—to gain a thrilling view of cerebral structures at the molecular level. From there, she recalls, she went on to explore sites of communication between brain cells, called synapses, falling
“in love with their incredible intricacy.
“I became focused on wanting to understand
how we build billions of these complex structures
so reliably during normal development, and how
a failure in this process may lead to developmental disorders like those that I observed working
with children with special needs.”
Her early fascination with neuroscience has
spawned a career rich in research. Today, Rochelle Hines, along with her husband and collaborator Dustin Hines, is rapidly expanding our
understanding of how, for better or worse, neuronal activity patterns guide human behavior
and ultimately contribute to pathology.
“Patterned activity in the brain is achieved
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through a balanced relationship between ‘on’
signals originating from excitatory cells and ‘off’
signals from inhibitory cells that act to modulate
the activity of the excitatory cells,” she says. Her
focus, she adds, tends toward the inhibitory
cells, cellular “dimmer switches” that finely tune
levels of excitation in the brain.
“Rochelle and I have a common thread, in
that we both study cells in the brain that modulate brain activity patterns,” says Dustin, noting
that he focuses more on the brain’s abundant glial
cells, which surround neurons and provide support for and insulation between them.
The couple, who recently moved to Las Vegas
together to continue their research in UNLV’s
psychology department, shares an interest in this
area of neuroscience for a number of reasons.
“The subject of modulatory cells has been attractive to us, as many studies are now pointing
to this area as the most likely avenue for therapeutic advancement,” says Dustin, noting that
pharmaceutical companies have been interested
in his research. “We also enjoy working in these
areas because, to date, they are largely understudied in neuroscience. So it’s exciting to work
on topics where there are a lot of new discoveries and advancements to be made.”
The two researchers, who met early in their
careers, work synergistically. Both explore the
functioning of these modulatory systems in the
brain, but each has a specialty area. Rochelle uses a
molecular and cellular approach to focus on
interneurons, also called “relay neurons,” cells that

modulate communication between other neurons.
Dustin’s work with glial cells, specifically astrocytes
and microglia, involves a cellular physiological and
behavioral approach to understand how glia
modulate neuronal communication.
His research has implications for degenerative maladies such as depression and stroke. For
example, one of his studies examined how the
chemicals activated in sleep deprivation may be
used to help diminish depression. His research
team used an animal model to examine how a
certain compound that affects adenosine receptors in the brain mimics sleep deprivation and
improves mood and behavior.
He believes glial cells have been largely overlooked in brain research and provide an oasis for
novel therapeutics.
“The tools that were needed to study glial
cells were not available early on in neuroscience
research,” he says. “After World War II, many electrical technologies used to detect submarines, like
oscilloscopes, drove the research; consequently,
the electrical properties of neurons became the
focus of the field. In the late 1980s, the development of new microscopes and genetic tools allowed us to see how glial cells contribute to brain
function by modulating neurons.”
Rochelle’s research, meanwhile, examines
how interneurons and inhibitory synapses
affect neurodevelopmental disorders such as
autism and schizophrenia. By investigating the
activities of inhibitory cells in the brain—those
“dimmer-switch” cells that finely tune

PARTNERS IN MIND Husband-and-wife team
Dustin and Rochelle Hines research brain cells
in their quest for solutions to degenerative
diseases and developmental disorders.
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levels of excitation—she seeks to learn more
about the development of signaling in the
nervous system.
“Excitatory signaling can be thought of as a
typical light switch, either fully on or fully off,”
she says, adding that inhibitory signaling modulates this activity, allowing for subtler variations
of brain activity.
Like her husband, Rochelle chose to study a research area that has abundant potential for discovery.
“The role of inhibitory signaling is becoming
increasingly apparent, and much of it is based on
the symptoms associated with these disorders as
well as studies in postmortem tissue from human
subjects with these disorders,” she says.
She recently authored an article describing a
study of inhibitory receptors in the brain and
how certain inhibitory synapses might contribute to the symptoms of schizophrenia.
“These receptors are the target for many
drugs that are in wide clinical use, including anesthetics and anti-anxiety and sleep drugs, so we
know that they are a powerful target,” she says.
Her work has also garnered the interest of pharmaceutical companies.
The couple has more than 50 scholarly journal articles between them. By the end of the year,
they expect to submit their first jointly authored
article emanating from their UNLV research. It
will focus on how the brain regulates sleep.
—Sue DiBella

Smoking and Schizophrenia

Y

ou might be surprised to learn that the
smoking rate for schizophrenic patients is
45 to 88 percent higher than the general
population’s, according to “Co-Morbidity of
Smoking in Patients With Psychiatric and Substance Use Disorders,” published in the American Journal on Addictions. And if you wonder
what the underlying cause of such a pervasive
habit might be, you’re not alone.
Xiangning Chen and Jingchun Chen of the
UNLV Nevada Institute of Personalized Medicine
(NIPM) are looking to genetics for the answer.
“Genetics actually influences everything we are
and do,” Xiangning Chen says. “Genetics defines
your potential or capacity, and how you reach that
capacity depends on the environment you’re in.”
People with schizophrenia can experience
delusions, hallucinations, dissociations from
reality, abnormal social behavior, erratic speech
and behavior, and the inability to focus and
recall information. Although environmental
factors may contribute to the development of
schizophrenia, the disorder has been linked
to specific genetic variants that predispose a
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SMOKE AND PEERS Xiangning Chen (right) and
Jingchun Chen (left) look at genes to clear the air on
the link between schizophrenia and smoking.

person to developing the condition.
“Researchers have performed a lot of twin
studies and family studies with respect to schizophrenia,” Jingchun Chen says. “The results show
time and again that the more overlap people have
in their genetic makeup, the greater their chances
are for developing this disorder. For instance, if
one twin sibling has schizophrenia, the other has
a 50 percent chance of developing it as well. So
there’s clearly a genetic component.”
Previous research has noted a strong correlation between heavy smoking and schizophrenia. A 2011 finding in the journal Psychiatric
Services, for example, concluded that the “prevalence of smoking has remained alarmingly
high among individuals with schizophrenia
and bipolar disorder in routine psychiatric settings.” Although there is some dispute among
researchers as to why, the most commonly cited explanation is that patients are attempting
to “self-medicate.” In short, researchers have
concluded schizophrenic patients smoke because it makes them feel better.
Xiangning Chen and Jingchun Chen
wondered whether genetics might play a role in
creating this analgesic effect.
Supported in part by separate grants from
the National Institutes of Health, Xiangning
Chen and Jingchun Chen examined genes
associated with both schizophrenia and smoking
to determine whether the disorder and nicotine
dependence might be linked. Using sophisticated
analytic techniques as well as data on the genetic
components involved in the general population’s
smoking behavior, the two discovered that while

there was likely a genetic predisposition to
smoking in schizophrenics, the cause of
schizophrenic patients’ excessive tobacco use
was not entirely due to nicotine dependence or
addiction, as is often the case with smokers in
the general population.
“Schizophrenic patients have some unique behavioral factors that cause them to smoke, and
smoke quite a bit,” says Xiangning Chen, a professor in both UNLV’s Department of Psychology and
NIPM. “One of the challenges for schizophrenic
patients is that they cannot remember things accurately, follow their thoughts easily, or concentrate effectively. Therefore, they use cigarettes to
help them cope and overcome some of the symptoms caused by the disorder, as one effect of nicotine on humans is to improve cognitive function.”
Although schizophrenic patients are smoking
for reasons that extend beyond what their genomes might predispose them to, the discovery of
genetic liability between the schizophrenia and
smoking has troubling implications.
“Schizophrenia and smoking are considered
complex disorders, meaning that more than one
gene contributes to them,” says Jingchun Chen,
an assistant professor at NIPM. “Because we
found some genes and pathways that are shared
between schizophrenia and smoking, we now
believe that smoking may actually increase the
risk of schizophrenia developing in a person
who has these genes, so the next step is to find
out what the function of those genes are.”
The scientists say their work to pinpoint
those genes could one day lead to personalized
treatments aimed at improving patients’ quality
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of life or even preventing the condition entirely.
The two researchers indicate that their plan to
take advantage of the capacity of UNLV’s Cherry
Creek II supercomputer, one of the fastest and
most powerful supercomputers in the world,
should enhance their ability to deliver results.
In the meantime, they say, they’ll be looking at
genes associated with other disorders and diseases
to see if these might also be related to schizophrenia. At this point, for example, the researchers
know that schizophrenic patients have an increased chance of developing an autoimmune disorder—and vice versa—and are working to determine what genetic liability might link the two.
Another project involves using Cherry Creek
II to look for genetic ties between smoking and
lung cancer—that is, whether a gene or set of
genes might predispose a person to lung cancer,
nicotine addiction, or both. Contrary to popular
belief, Xiangning Chen says, the relationship between cigarette smoking and lung cancer is
much more complicated.
“Smokers that develop or die of lung cancer
are actually the minority,” Xiangning Chen says.
“If smoking directly caused lung cancer, you’d
expect to see more of it.”
Discovery of genetic roots in disease and disorder rests at the heart of NIPM’s mission. If research can determine which genes cause a particular condition, a “personalized” treatment
strategy can be established. This would eliminate expensive guesswork associated with treatments that patients may or may not respond to,
while increasing the likelihood of an individualized treatment’s success at the same time.
“I never expect that what I do will change the
world,” Xiangning Chen says. “But what I can do
is give people something to think about from the
information I can give them. If you find out you
carry a gene that predisposes you to lung cancer,
for example, maybe you won’t smoke. That’s
what NIPM and researchers like me are here
for—to try to find a way to better treat people and
help them make more informed decisions.”
— Raegen Pietrucha

A Powerful Protein

C

ell and molecular biologist Nora Caberoy
never thought that a protein she worked
with years ago could potentially lead to new
discoveries in the fight against Alzheimer’s disease. But that’s exactly what the protein, called
“tubby” because it is encoded by the TUB gene,
may offer scientists.
It all started in 2007 while Caberoy, now an
assistant professor in UNLV’s School of Life Sciences, was working as a postdoctoral fellow at
the Bascom Palmer Eye Institute in Miami.
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While occupied with a project related to macular degeneration—a retinal condition that
causes a loss in central vision—she identified a
tubby protein that is involved in the clearance of
photoreceptor debris in the eye.
Photoreceptors are cells responsible for
reception and processing of light as well as
sending the signal to the brain. When old bits of
cellular debris accumulate around the ends of
photoreceptors, these need to be removed.
Specialized cells make this happen, but they
need proteins to guide the process.
This is where tubby comes in. Tubby proteins
bind onto cellular debris while inviting another
type of cell, phagocytes, to begin clearing it.
Tubby serves, in other words, as a bridge between
the cells that need to be consumed and those that
are supposed to eat them.
So, what does all this have to do with Alzheimer’s disease? Patients with Alzheimer’s have an accumulation of amyloid beta, a protein that aggregates in the brain. Caberoy says that, for reasons
that are not entirely clear, the amyloid beta deposits of those with Alzheimer’s squeeze in between
the brain cells, eventually killing them.
“We all produce amyloid beta, but in healthy
individuals, the production of amyloid beta is
somehow equal to the degradation,” she says. “In
those with Alzheimer’s, the balance is not equal.”
According to Caberoy, the body maintains
this balance in part thanks to the work of debrisand pathogen-eating microglial cells that, in addition to gobbling up diseased cells, also have a
taste for excess amyloid beta. But many scientists
suspect that this microglial assault may have a
serious side effect: an increase in inflammation
that may hasten the disease’s progress and the
subsequent death of brain cells.
Caberoy noted from her research on photoreceptors that the tubby protein assisted in the
removal of damaged cells in the eye without inflammation. Could they perhaps be repurposed
for use in the brain?
“We know that the active receptor in the eye
also is present in the brain, but for some reason, it
is not the preferred receptor,” she said. “We also
know that the molecules that bridge that amyloid
beta are not binding directly to the receptor.”
In an attempt to encourage such binding, Caberoy is working to create a new type of molecular
“bridge,” one that could link amyloid beta to a less
inflammatory protein that might neutralize it.
In the lab, her research team undertook
screenings to discover proteins that could bind to
amyloid beta. They were able to identify several.
Caberoy then “optimized” these proteins by
mutational analysis until she found one that could
bind to the most toxic form of amyloid beta.
“I fused the amyloid beta binding protein to
the part of tubby that recognizes the silent

receptor,” she said. “Through testing, we were
able to show that chimeric protein, which is
created through the joining of two or more
separate proteins, was able to bind to both the
receptor and the amyloid beta. We also found
that this process could reduce the production of
inflammatory factors.”
Over the next few months, Caberoy’s
research team will test this process on mice with
Alzheimer’s. She says they will first inject the
affected mice with the chimeric protein, then
see if it results in a reduction in the level of
amyloid beta in the brain with the production of
inflammatory factors in the blood.
If successful, this process will bolster the
patent application Caberoy has submitted for
this method of clearing amyloid beta.
Additionally, if the results are positive, the
approach could eventually be used to develop
therapies for human patients, although she
cautions that there are still questions as to
whether such treatment would need to be
deployed before the disease develops or if it
might help individuals already affected.
Regardless, she says, there is much to be
hopeful about.
“There could be clinical applications where
we would produce proteins that could be injected into an individual,” she says. “You can imagine someone that has a family history of Alzheimer’s disease taking a pill or getting an injection before the disease develops.”
— Shane Bevell

Learning From Cancer

U

NLV biochemist Ron Gary is deeply interested in physiological processes affecting
human health, a fact that’s not immediately obvious as one gazes down at the petri dishes
positioned around his lab. But Gary’s molecularlevel work with the cells housed in these dishes
continues to yield important cancer-related discoveries and, more recently, potentially gamechanging neuroscientific findings related to Alzheimer’s disease.
The Alzheimer’s discoveries were an outgrowth of the cancer research. Gary and his laboratory team were working to learn whether inhibiting the aberrant activity of a particular “signaling” enzyme, glycogen synthase kinase-3
(GSK-3), might slow the explosive growth of
cancer cells. Because the enzyme has also been
implicated in the development of Alzheimer’s,
Gary’s team soon found themselves thinking
about the ways in which inhibiting GSK-3 might
affect a key component of that disease as well.
There are two microscopic structures that
are characteristically found in the brains of
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DOUBLE TROUBLE
Ron Gary’s enzyme
research serves two
purposes; cancer and
Alzheimer’s, beware.

EYES WIDE OPEN
Nora Caberoy
discovered that her
research on proteins
in the eye might
someday help us
fight Alzheimer’s.

“There could be clinical applications where we would produce [tubby] proteins that could be injected into an individual,” says Caberoy. “You can imagine
someone that has a family history of Alzheimer’s disease taking a pill or getting an injection before the disease develops.”

Alzheimer’s patients: plaques and neurofibrillary
“tangles.” At the molecular level, neurofibrillary
tangles are perhaps the illness’s most
distinguishing feature. The tangles are composed
of tau—proteins that, when working normally,
play a key role in transporting nutrients and
other important materials throughout the cell.
When tau proteins aggregate in the brain and
form tangled clumps, the transportation system
breaks down, cells begin to die, and Alzheimer’s
symptoms appear.
Gary, a professor in UNLV’s Department of
Chemistry and Biochemistry, suspects that
GSK-3 may be inadvertently inducing tau tangling by accelerating a process called phosphorylation—a crucial metabolic step by which,
under normal circumstances, cells regulate
various molecular processes.
“Though we don’t know why it becomes
overactive and produces tangled tau, our thinking is that, if you could suppress or slow that
phosphorylation activity of GSK-3, you could
stop or slow the formation of tau tangles,” Gary
says. “Then maybe you could prevent or slow the
progression of Alzheimer’s.”
In order to reduce GSK-3 and suppress the
formation of tangles, Gary says, researchers
would need to develop an inhibitor, a compound
or drug that would depress its activity. Gary and
his team of students are working to do just that.
“We take human cells of brain origin, treat
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them with different drugs in a dish, and look at
the molecular consequences of that treatment,” he
said. “You can’t just eliminate the GSK-3 enzyme,
because that would be problematic as well.”
Gary says a handful of key questions are
guiding his lab team’s efforts. What are the consequences more broadly throughout the cell,
and specifically, do different types of inhibitors
do the same thing throughout the different areas where GSK-3 has a function? Or could different inhibitors have subtly different effects on
GSK-3-related systems?
Gary says he’s also interested in examining
beta-catenin, another important molecule influenced by GSK-3. Beta-catenin plays a crucial role in
the control of cell growth. If out of balance, it could
potentially be a contributing cause of cancer.
According to Gary, when you inhibit GSK-3
with the goal of reducing tau tangles, it seems
likely you would also reduce the phosphorylation of beta-catenin.
“You would initially assume that any
inhibitor that suppresses GSK-3 enzyme
activity would have a similar effect on betacatenin, but we found that different inhibitors
have different effects on beta-catenin,” he
says. “This is important because Alzheimer’s
work covers everything from treating patients
to the other end of the spectrum, looking at
molecular effects in isolated cells. But if we
ever want to use this class of compound to

treat patients, we would want to know what
else happens in the cell when you suppress
tau phosphorylation by inhibiting GSK-3.”
— Shane Bevell

Treatments in Balance

M

uch like other parents, Merrill Landers, a
father of four who chairs UNLV’s Department of Physical Therapy, often admonishes his children to go outside and play. Sometimes, he admits, he does this so that he and his
wife have a moment’s peace. More often, he
says, it’s to encourage his children to be more
physically active. Landers knows that outdoor
activities such as running around in the yard,
kicking a soccer ball, or riding a bicycle are crucial to the growth and development of healthy
young bodies.
And that may not be the only benefit. According to recent research findings, Landers indicated,
an accumulation of steady physical activity during our youth and college years may generate a
protective effect in the brain—one that could reduce the risk of, or even prevent, neurodegenerative diseases like Parkinson’s disease.
Landers’ research has focused on Parkinson’s disease since he joined the UNLV faculty
in 2001. His recent work involves examining
how exercise might influence the disease’s
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CURRENT AFFAIRS
Brach Poston’s
research on
electrical stimulation
shows promise for
Parkinson’s patients.

BALANCING
ACT Physical
activity can help
protect us from
Parkinson’s, Merrill
Landers says.

“Falling represents one of the two leading causes of premature death among people with Parkinson’s disease,” says Merrill Landers. “Falling can cause the
domino effect of fractures to surgery to postoperative complications to other falls. For me, preventing falls is a big issue.”

course and determining whether patients’
physical activity might improve their balance
and walking—work that has neatly segued into
a broader set of findings on activity and neurodegenerative protective effects within the field,
he indicated.
The four cardinal signs in Parkinson’s disease, Landers says, are bradykinesia (slowness of
movement), rigidity, resting tremors, and postural instability (poor balance). The first three
respond to and can be improved with medication. Postural instability does not respond to Parkinson’s disease medications; the only treatment
approach that has been demonstrated to be beneficial is balance training.
“Falling represents one of the two leading
causes of premature death among people with
Parkinson’s disease,” says Landers. “The first is
aspiration pneumonia. Falling can cause the
domino effect of fractures to surgery to postoperative complications to other falls. For me, preventing falls is a big issue.”
One aspect of Parkinson’s disease that
piques Landers’ curiosity is how falls affect people with the disease. Healthy adults typically
evaluate the circumstances of a fall in two ways.
If it’s a fluke, they forget about it. If there is a
reasonable chance the fall could happen again,
they seek ways to prevent future tumbles.
For people with Parkinson’s disease, it’s
more complicated. A fall may cause anxiety or
fear, emotions that may result in an unhealthy
avoidance of normal activities. They may limit
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visits to friends, attending church, or venturing
out in public. Some become reclusive, a condition that can initiate a spiral of declining
health. When fall-averse people with Parkinson’s disease seldom leave their homes, they
tend to lose strength, coordination, and balance. These deficits, in a cruel irony, make them
more susceptible to falling in their homes as
they move from room to room.
“Some level of fear is good and can be protective, but too much can become harmful, especially in this disease population,” says Landers.
“Those who shouldn’t be going out can be
coached to become more careful and trained to
improve their balance. Those who have high levels of fear need additional help.”
During a study involving older adults, Landers first measured “balance characteristics,” or
participants’ ability to balance, while asking
them to self-report their “balance confidence.”
He followed the study participants for one year,
noting when and how often they fell. The results
indicated the self-assessments were the best predictors of future falls. The next best predictor
was fall-avoidance behavior.
Using data obtained from another study,
Landers helped rebuild the confidence of
those who reported lower levels of balance
and stability. Balance training became a key
prescription.
As with his own children, Landers says, adults
need exercise to maintain and strengthen muscles.
Most people with Parkinson’s disease are

prescribed a regimen of low-intensity exercise—a
level so low, Landers says, it’s ridiculous.
“When we look at someone with Parkinson’s
disease and see the poor posture and the slow
movements, we assume he or she can’t handle
exercise. I think this is a big misconception and
became something I wanted to test.”
In 2015, Landers led an “exercise boot camp”
study to evaluate the ability of people with Parkinson’s to handle high-intensity exercise, which
comprised three components: strength exercises
at greater than 70 percent of the person’s onerepetition maximum, endurance exercises at 70
to 75 percent of the person’s estimated maximum heart rate, and exercises using dynamic
and challenging balance-coordination tasks.
The results were clear: Those with high-intensity workouts responded well to the increased level
of activity, and they did not experience more falls
than the low-intensity group. What’s more, they
enjoyed it—even more so than the low-intensity
group enjoyed their activity.
Landers next sought to determine whether
such intense exercise might act as an inhibitor of
the disease’s progression. Many studies among
laboratory animals had previously indicated that
exercise can protect the brain from the disease.
Some of the results even showed small animals
actually recovering from the disease.
Landers then found results from five or six
studies that indicated exercise during a person’s
early adult life could have a cumulative effect
and protect against the disease—that is, the risk
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for Parkinson’s decreased with an increase in
physical activity in early adult life. Those results,
he says, stimulated his curiosity further.
“As scientists, we know exercise benefits
many different body systems, but the evidence
strongly suggests that exercise also benefits our
brains,” Landers says. “Physiologically, exercise
—particularly aerobic exercise—increases a
chemical called brain-derived neurotrophic
factor, or BDNF, which stimulates neuronal
growth and helps potentiate neuroplasticity.
“BDNF is present when the brain learns a
new skill or motor task. It also protects neurons, including the dopaminergic neurons that
are affected by PD. So, presumably, having
greater quantities of BDNF will protect more of
those neurons, thereby slowing the progression
of the disease.”
Landers and his team are currently exploring
how BDNF (known to increase with aerobic exercise) and anti-inflammatory enzymes influence
disease progression and response to exercise, and
whether the successes with laboratory animals
might apply to human beings. If successful, the
study could further validate exercise as a neuroprotective strategy against Parkinson’s disease, either
preventing its onset or slowing its progression.
Landers plans to present his findings during
the World Parkinson Congress in Portland, Oregon, this October. He hopes his results will help
convince those working with Parkinson’s patients
that high-intensity exercise is not only safe but
more effective than low-intensity workouts.
In the future, Landers says his plans include
studying the effects of exercise during midlife
and later. He’ll also explore related genetic information, which might allow scientists to gain additional insights into gait and balance function
in those with Parkinson’s disease.
As for his children, Landers expects them to
make exercise a regular part of their lives. And
he plans to join them.
— Kevin Dunegan

Stimulating Parkinson’s Research

U

NLV’s Brach Poston is exploring how low
levels of electrical stimulation may contribute to improved motor performance in
people with neurodegenerative diseases such as
Parkinson’s disease.
And how did he choose this scientific path?
Foresight.
After earning a master’s degree in exercise
physiology from UNLV and a doctorate at the
University of Colorado, Boulder, Poston began
a postdoctoral program at Arizona State University. There he learned about brain stimulation, immediately recognizing its potential as
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the next “big thing” in his field.
“I was introduced to the methods of
transcranial magnetic stimulation [TMS] and
transcranial direct current brain stimulation
[tDCS],” Poston says. “I saw tDCS as a
promising [way] to help people, and I was
fortunate enough to be admitted to a postdoc
program at the National Institutes of Health
[NIH], where I was able to learn about this
type of stimulation.”
Poston spent the next year and a half studying how to use multiple noninvasive brainstimulation techniques. After reviewing studies from other scientists, he became convinced
that, as he puts it, “tDCS was most likely to be
the best noninvasive stimulation option for
aiding those with Parkinson’s disease.”
Parkinson’s is a disease of the basal ganglia,
an area of the brain that is vital to motor control and the production of dopamine. Dopamine is more known for its involvement in reward mechanisms and reinforcement learning
in the brain, but it also plays a crucial role in
mobility. When a person completes a complex
movement, action, or task, dopamine is required to enable the basal ganglia to assist his
or her motor cortex with movement planning,
execution, and learning.
When using tDCS to treat Parkinson’s patients, clinicians connect saline-soaked sponges
to rubber electrodes that are distributed across
the scalp. They then pass a weak electric current from one electrode to the other. The idea is
to use the current to excite or inhibit activities
that are thought to originate in specific areas of
the brain. For Parkinson’s disease patients,
these areas often include the motor cortex, a
part of the brain’s cerebral cortex associated
with muscular activity.
Preliminary findings by Poston and others
have shown promise: tDSC does appear, in fact,
to improve performance of simple motor tasks
performed by hands and arms. These tasks can
include using a pinch-grip movement to generate force against an object, retrieving small objects like buttons or coins, or performing an
arm movement to a target.
The electric current doesn’t cause the action to happen, Poston explains; it simply augments the normal increase in the “excitability
of cortical neurons” when a task is practiced.
When someone wants to lift an object—picking up a glass, for example—cortical neurons
become excitable and act to execute that movement. When you practice a particular action,
such as throwing a ball, the neurons become
more excitable over time. This leads to improved accuracy and efficiency of movement.
The lower levels of dopamine common
among Parkinson’s patients cause impairments

in the communication between the basal ganglia and the motor cortex, a breakdown that
reduces cortical neurons’ excitability during
m o v e m e n t e x e c u t i o n — t h u s t h e s l o we r
movements, reduced muscle activity, and less
accurate movements experienced by
Parkinson’s disease patients. By augmenting
excitability among cortical neurons when tasks
are being attempted, tDCS boosts motor control in the short term.
Although tDCS today is used only on outer
areas of the brain, Poston believes—based on
study results involving animal models—the
technique might one day be used to elicit effects within deeper brain structures.
Poston’s first studies at UNLV sought to
identify the optimal method for one-time tDCS
treatment among people with the disease. His
findings helped identify optimal placements of
electrodes, correct electric current strengths,
and optimal durations for stimulation.
With these parameters established, Poston
moved on to explore using daily stimulation to
treat patients during a two-week period. “During
a single treatment, we and other research groups
have typically seen a 10 to 15 percent performance improvement, with the effects lasting up
to 90 minutes,” he says. “Daily application could
produce a cumulative effect, and we hope to be
able to elicit performance improvements of approximately 30 percent, which were seen in
studies among young adults, when we apply
stimulation over a two-week period.”
Poston also broke some new ground last
summer by using tDCS on the cerebellum. This
hasn’t been done in Parkinson’s disease before
but has been shown to increase motor performance in both younger and older adults. The
rationale for this is that, because the cerebellum has been shown to compensate for impaired basal ganglia activity in Parkinson’s disease, applying tDCS to excite the cerebellum
may enhance this compensation.
Poston’s previous and current studies focus
exclusively on the hands and arms, but he says
he now has the funding that will enable him to
test tDCS while a person is walking. Doing this
will involve Parkinson’s disease patients walking on a treadmill. The goal is to determine
how tDCS treatments affect patients’ stride
length, velocity, and movement variability.
So far, Poston says his results are positive
and that, in the future, he expects the treatment
to become a more widely used adjunctive therapy. He also says that affordable, wearable
tDCS devices have a realistic potential to become available for home use, a place where patients or caregivers could easily apply the stimulation as needed.
— Kevin Dunegan
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